Registration on GlobalERFx. com is necessary to be able to gain access to the different Procuring Companies where the ERFxs are issued. Registration carries no fee and the user will be e-mailed with login details.
Pipeline At LifeCycle Pharma we are building a broad portfolio of products to enhance the likelihood of commercial success. To attain this goal, we are creating value-added formulations of several approved and marketed drugs in a number of important therapeutic areas. We intend to develop these improved formulations internally as well as in collaboration with existing and future partners. Our goal is to maximize the value of our business by retaining substantial commercial rights or profit sharing opportunities to our products and developing them through a combination of in-house clinical development and out-licensing of both early- and late-stage programs. We intend to identify product opportunities from approved drugs where we see an opportunity to improve the clinical performance of the product either by increasing the effectiveness of the drug and/or by decreasing unwanted side effects.
Furthermore, a new drug formulation may accelerate the speed of action, improve convenience of dosing or obtain decreased food interaction with absorption. The MeltDose® technology has allowed us to bring each of our product candidates from program initiation to first human dose (clinical studies) in less than 12 months. The typical development period from program initiation to regulatory submission for reformulated drugs is 3-5 years, while conventionally developed drugs typically require between 10 and 12 years before they can be submitted for regulatory approval. LifeCycle Pharma is focusing its efforts on six clinical drug candidates: